SeaCrest Wealth Management LLC Sells 352 Shares of Moderna, Inc. (NASDAQ:MRNA)

SeaCrest Wealth Management LLC reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 5.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,617 shares of the company’s stock after selling 352 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Moderna were worth $705,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Quattro Financial Advisors LLC increased its holdings in Moderna by 87,879.8% in the 1st quarter. Quattro Financial Advisors LLC now owns 87,100 shares of the company’s stock valued at $9,281,000 after buying an additional 87,001 shares during the period. Little House Capital LLC bought a new stake in shares of Moderna during the 1st quarter valued at approximately $329,000. Mayfair Advisory Group LLC grew its holdings in shares of Moderna by 6.0% during the 1st quarter. Mayfair Advisory Group LLC now owns 2,164 shares of the company’s stock valued at $231,000 after purchasing an additional 122 shares during the last quarter. 180 Wealth Advisors LLC grew its holdings in shares of Moderna by 4.8% during the 1st quarter. 180 Wealth Advisors LLC now owns 14,708 shares of the company’s stock valued at $1,567,000 after purchasing an additional 675 shares during the last quarter. Finally, Sound Income Strategies LLC grew its holdings in shares of Moderna by 41.3% during the 1st quarter. Sound Income Strategies LLC now owns 1,077 shares of the company’s stock valued at $115,000 after purchasing an additional 315 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO James M. Mock sold 705 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a total transaction of $71,860.65. Following the transaction, the chief financial officer now directly owns 5,048 shares of the company’s stock, valued at $514,542.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $107.12, for a total transaction of $1,606,800.00. Following the transaction, the director now directly owns 2,071,931 shares of the company’s stock, valued at $221,945,248.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 705 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the transaction, the chief financial officer now directly owns 5,048 shares in the company, valued at $514,542.64. The disclosure for this sale can be found here. Insiders have sold a total of 396,255 shares of company stock valued at $54,593,731 over the last ninety days. 15.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MRNA. Evercore ISI reaffirmed an “in-line” rating and set a $120.00 price target on shares of Moderna in a report on Thursday, June 27th. Piper Sandler reaffirmed an “overweight” rating and set a $214.00 price target on shares of Moderna in a report on Thursday, June 27th. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. UBS Group boosted their target price on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, June 28th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $134.02.

Moderna Stock Performance

Shares of NASDAQ MRNA opened at $115.95 on Thursday. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03. The company’s 50 day moving average price is $134.68 and its 200-day moving average price is $112.65.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. Moderna’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.19 EPS. Research analysts forecast that Moderna, Inc. will post -7.46 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.